VAXART INC. - COMMON STOCK

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

02 12 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

13 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

07 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

24 10 2024 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

15 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

30 9 2024 15:12:22 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

28 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

08 8 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

02 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update

17 6 2024 15:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

17 6 2024 14:51:57 提供 NetDania Notify

Vaxart Announces $40 Million Underwritten Offering of Common Stock

13 6 2024 18:07:26 提供 Nasdaq GlobeNewswire

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

13 6 2024 15:15:11 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 5 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

13 5 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

07 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

30 4 2024 07:00:39 提供 Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

27 3 2024 07:00:00 提供 Nasdaq GlobeNewswire